Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-02
2007-01-02
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S009100, C514S015800, C530S300000, C530S317000, C530S327000, C530S345000
Reexamination Certificate
active
10433295
ABSTRACT:
Fumaric acid amides of the general formula (I)wherein R1represents OR3or a D- or L-amino acid radical —NH—CHR4—COOH bonded via an amide bond, wherein R3is hydrogen, a straight-chained or branched, optionally substituted C1-24alkyl radical, a phenyl radical or C6-10aralkyl radical and R4is a side chain of a natural or synthetic amino acid and R2represents a D- or L-amino acid radical —NH—CHR5—COOH bonded via an amide bond or a peptide radical comprising 2 to 100 amino acids bonded via an amide bond, wherein R5is a side chain of a natural or synthetic amino acid, are used for preparing a drug (1) for the therapy of an autoimmune disease; (2) for use in transplantation medicine; (3) for the therapy of mitochondrial diseases; or (4) for the therapy of NF-kappaB mediated diseases.
REFERENCES:
patent: 2993837 (1961-07-01), Millar et al.
patent: 3832287 (1974-08-01), Gale et al.
patent: 4515974 (1985-05-01), Zecher et al.
patent: 4746668 (1988-05-01), Sato et al.
patent: 4851439 (1989-07-01), Speiser et al.
patent: 4959389 (1990-09-01), Speiser et al.
patent: 5149695 (1992-09-01), Speiser et al.
patent: 5214196 (1993-05-01), Blank
patent: 5242905 (1993-09-01), Blank
patent: 5359128 (1994-10-01), Blank
patent: 5424332 (1995-06-01), Speiser et al.
patent: 5451667 (1995-09-01), Speiser et al.
patent: 5538968 (1996-07-01), Chiesi et al.
patent: 5548059 (1996-08-01), Bayley et al.
patent: 5589504 (1996-12-01), Dannenberg et al.
patent: 5763408 (1998-06-01), Nishikawa et al.
patent: 5972363 (1999-10-01), Clikeman et al.
patent: 6277882 (2001-08-01), Joshi et al.
patent: 6355676 (2002-03-01), Joshi et al.
patent: 6359003 (2002-03-01), Joshi et al.
patent: 6436992 (2002-08-01), Joshi et al.
patent: 6509376 (2003-01-01), Joshi et al.
patent: 2003/0013761 (2003-01-01), Joshi et al.
patent: 2248955 (2002-08-01), None
patent: 25 30 372 (1977-01-01), None
patent: 26 21 214 (1977-11-01), None
patent: 38 34794 (1990-04-01), None
patent: 0 103 274 (1984-03-01), None
patent: 1 216 699 (1970-12-01), None
patent: 1 422 726 (1976-01-01), None
patent: WO 89/01930 (1989-03-01), None
patent: WO 94/28883 (1994-12-01), None
patent: WO 95/25102 (1995-09-01), None
patent: WO 96/02244 (1996-02-01), None
patent: WO 96/27369 (1996-09-01), None
patent: WO 97/48400 (1997-12-01), None
patent: WO 98/04290 (1998-02-01), None
patent: WO 98/27970 (1998-07-01), None
patent: WO 99/21565 (1999-05-01), None
SE Holroyd, et al. Rational design and binding of modified cell-wall peptides to vancomycin-group antibiotics: factoring free energy contributions to binding. (1993) Tetrahedron, 49, 9171-9182.
K.S. Murthy, J. Pharm. Sci. (1993) 82(2), pp. 113-126.
J.M. Aiache, J. Pharm. Biomed. Anal. (1990) 8(6), pp. 499-506.
Dethlefsen, L.A., “Toxic Effects of Acute Glutathione Depletion by Buthionine Sulfoximine and Dimethylfurnate on Murine Mammary Carcinoma Cells,” Radiation Research, vol. 114, 1988, pp. 215-224.
Gordon, G.B., et al., “Induction of NAD(P)H:quinone reductase in human peripheral blood lymphocytes”, Carcinogenesis, vol. 12 (12), 1991, pp. 2393-2396.
Hildebrandt, H., “Pschyrembel Klinisches Woerterbuch Ed. 258”, 1998, Walter de Gruyter, New York, XP 002234302, p. 182, col. 1, paragraph 2 and p. 1469, col. 1, paragraph 16-col. 2, paragraph 1. Not translated.
Hohenegger, M., et al., “Nephrotoxicity of Fumaic Acid Monoethylester (FA ME)”, Advances in Experimental Medicine and Biology, US 1989, vol. 252, pp. 265-272.
Kuroda, K, et al., “Fumaric Acid Enhances DNA Synthesis of Rat Hepatocytes by Counter Acting the Toxicities of Mitomycin C and Atlatoxin B1”, Jpn. J. Cancer Res. (Gann), Aug. 1986, vol. 77, pp. 750-758.
Lehnert, S., et al., “Radiation Response of Drug-Resistant Variants of a Human Breast Cancer Cell Line: The Effect of Glutathione Depletion”, Radiation Research, vol. 124, 1990, pp. 208-215.
Miller, A.C., et al., “Posttranscriptional Down-Regulation of ras Oncogene Expression by Inhibitors of Cellular Glutathione”, Molecular and Cellular Biology, Jul. 1993, vol. 13, No. 7, pp. 4416-4422.
Mrowietz, U., “Nephrotoxische Wirkung durch Fumarsaure”, Hautarzt, 2000-51:615, Springer-Verlag 2000, p. 615. Not translated.
Odom, R.Y., et al., “Cancer Chemoprotective Agents Inhibition of Human HT29 Colon Carcinoma Cell Proliferation is Reversed by N-Acetyl Cysteine”, Proceedings of the American Assoc. for Cancer Research Annual No. 41, Mar. 2000, p. 342, XP008017517.
Orta, T., et al., “Glutathione manipulation and the radiosensitivity of human tumour and fibroblast cell lines”, Int. J. Radiat. Biol., 1995, vol. 68, No. 4, pp. 413-419.
Pearl, J.M., et al., “Fumarate-enriched blood cardioplegia results in complete functional recovery of immature myocardium”, Annals of Thoracic Surgery, vol. 57, No. 6, 1994, Abstract only, 1 page.
Peeters, A.J., et al., “Fumaric Acid Therapy for Psoriatic Arthritis. A Randomized, Double-blind, Placebo-controlled Study”, British Journal of Rheumatology, vol. XXXI, No. 7, Jul. 1992, pp. 502-504.
Pereira, M.A., et al., “Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents”, Carcinogenesis, vol. 15, No. 5, 1994, pp. 1049-1054.
Prochaska, H.J., et al., “Elevation of Gluthathione Levels by Phase II Enzyme Inducers: Lack of Inhibition of Human Immunodeficiency Virus Type 1 Replication in Chronically Infected Monocytoid Cells,”, Molecular Pharmacology, vol. 45, No. 5, 1994, pp. 916-921.
Prochaska, H.J., et al., “Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication”, Proc. Natl. Acad. Sci., USA, vol. 90, May 1993, pp. 3953-3957.
Rao, C.V., et al., “Chemoprevention of Azoxymethane-Induced Colon Cancer by Ascorbylpalmitate, Carbenoxolone, Dimethylfumarate and p-Methoxyphenol in Male F344 Rats”, Anticancer Research, vol. 15, 1995, pp. 1199-1204.
Rao, K.S., et al., “Antihepatotoxic activity of monomethyl fumarate isolated fromFumaria indica”, Journal of Ethnopharmacology, vol. 60, 1998, pp. 207-213.
Roodnat, J.I., et al., “Akute Niereninsuffizienz bei der Behandlung der Psoriasis mit Fumarsaure-Estern”, Schweiz. Med., Wschr., vol. 119, nr 2, 1989, pp. 826-830. Not translated.
Spencer, S.R., et al., “Induction of Glutathione Transferases and NAD(P)H:Quinone Reductase by Fumaric Acid Derivatives in Rodent Cells and Tissues”, Cancer Research, vol. 50, 1990, pp. 7871-7875.
Steele, V.E., et al., “Preclinical Efficacy Evaluation of Potential Chemopreventive Agents in Animal Carcinogenesis Models: Methods and Results From the NCI Chemoprevention Drug Development Program”, J. of Cellular Biochemistry, Supplement 20, 1994, pp. 32-54.
Su, Jean Y.C., et al., “Reduction of H2O2-evoked, intracellular calcium increases in the rat N18-RE-105 neuronal cell line by pretreatment with an electrophilic antioxidant inducer”, Neuroscience Letters, 273, 1999, pp. 109-112.
Vandermeeren, M., et al., “Dimethylfumarate is an Inhibitor of Cytokine-Induced Nuclear Translocation of NF-kB1, But not Re1A in Normal Human Dermal Fibroblast Cells,” The Journal of Investigative Dermatology, vol. 116, No. 1, Jan. 2001, pp. 124-130.
Vandermeeren, M., et al., “Dimethylfumarate is an Inhibitor of Cytokine-Induced E-Selection, VCAM-1, and ICAM-1 Expression in Human Endothelial Cells”, Biochemical and Biophysical Research Communications, vol. 234, 1997, pp. 19-23.
Wang, X., et al., “Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase”, British Journal of Cancer, vol. 80(8), 1999, pp. 1223-1230.
Weinmann, I., et al., “Influence of Fumaric Acid Derivatives on T Lymphocytes in the Murine Model of HSV-1 Keratitis”, IOVS, vol. 41, No. 4, Mar. 15, 2000, XP008017516, pp. S146.
Altmeyer, P. et al., “Systemische Therapie der Psoriasis”,
Joshi Rajendra Kumar
Strebel Hans-Peter
Fumapharm AG
Kosar Andrew D.
Tsang Cecilia J.
Yeung Constance
LandOfFree
Fumaric acid amides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fumaric acid amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fumaric acid amides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3804497